Evolution of Views on Pathogenesis and Treatment of Immunoglobulin A-Nephropathy: What’s New Today?

Immunoglobulin A nephropathy is the most common immune glomerulopathy in the world. Significant evolution of views on the pathogenesis and treatment of the disease is especially noticeable in recent years due to the emergence of new data on the pathogenesis. It has been proven that immunoglobulin A nephropathy develops as a result of changes in the immune response of the mucous membranes, primarily the nasopharynx (tonsillitis) and gastrointestinal tract. The Russian population of patients is distinguished by its high prevalence, more significant clinical and morphological manifestations and rates of progression, higher proteinuria and prevalence of arterial hypertension and lower renal survival than in Asian and European populations. Immunoglobulin A nephropathy is one of the causes of terminal renal failure and the need for renal replacement therapy using dialysis and kidney transplantation, which requires a more active approach to therapy. The basis for managing patients with immunoglobulin A nephropathy, in accordance with clinical guidelines, is supportive therapy, including lifestyle changes, dietary correction, and drug therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Treatment methods that reduce glomerular inflammation include immunomodulatory and anti-inflammatory therapy. This lecture presents modern views on pathogenesis, diagnostics, and treatment (including tonsillectomy, fish oil, and various immunosuppressive therapy methods) based on clinical research results.

1. Schena F.P., Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin. Nephrol. 2018; 38(5):435-42. doi: 10.1016/j.semnephrol.2018.05.013.

2. Pitcher D., Braddon F., Hendry B. et al. Long-term outcomes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 2023; 18:727-38. https://doi.org/10.2215/CJN.0000000000000135.

3. Moriyama T., Tanaka K., Iwasaki C. et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014; 9:e91756. doi: 10.1371/journal.pone.0091756

4. Dobronravov V.A., Muzheczkaya T.O., Lin D.I. Immunoglobulin A nephropathy in the Russian population: clinical and morphological presentation and long-term prognosis. Nephrology. 2019; 23(6):45-60. doi: 10.36485/1561-6274-2019-23-6-45-60 [in Russian].

5. Batyushin M.M., Bobkova I.N., Vatazin A.V. Glomerular diseases: immunoglobulin A nephropathy. Clinical guidelines. 2021. [Electronic resource]. URL: https://rusnephrology.org/wp-content/uploads/2021/04/iga_060421-1.pdf. (date of the application: 29.01.2025) [In Russian].

6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4S):1-276.

7. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13(1):142-8.

8. Wheeler D.C., Toto R.D., Stefánsson B.V., et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021; 100(1): 215-24. doi: 10.1016/j.kint.2021.03.033.

9. Herrington W.G., Staplin N., Wanner C., et al., EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233.

10. McGrogan A., Franssen C.F., de Vries C.S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011; 26:414-430. doi: 10.1093/ndt/gfq665/

11. Yeo S.C., Goh S.M., Barratt J. Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology (Carlton). 2019; 24(9):885-895. doi: 10.1111/nep.13592.

12. Lai, K.N., Tang, S.C.W., Schena, F.P., et. al. IgA nephropathy. Nature Reviews Disease Primers. 2016; 2:16001. doi: 10.1038/nrdp.2016.1.

13. Zubkin M.L., Soldatov D.A., Frolova N.F. i dr. Current concepts of the pathogenesis of IgA nephropathy. Nephrology and Dialysis. 2024; 26(1):35-54. doi: 10.28996/2618-9801-2024-1-35-54 [in Russian].

14. Sallustio F., Curci C., Chaoul N. et al. High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transplant. 2021; 36(3):452-464. doi: 10.1093/ndt/gfaa264.

15. He J.W., Zhou X.J., Hou P. et al. Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy. Front Cell Infect Microbiol. 2021; 11:652837. doi: 10.3389/fcimb.2021.652837.

16. Zhao J., Bai M., Yang X. et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Renal. Failure. 2021; 43(1):928-933. doi: 10.1080/0886022X.2021.1936038.

17. Gesualdo L., Di Leo V., Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021; 43(5):657-668. doi: 10.1007/s00281-021-00871-y.

18. Rehnberg J., Symreng A., Ludvigsson J.F. et al. Infl amatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study. J Am Soc Nephrol. 2021; 32(2):411-423. doi: 10.1681/ASN.2020060848.

19. Kovács T., Kun L., Schmelczer M. et al. Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy? I. Study of intestinal permeability. Am J Nephrol. 1996; 16(6):500-505. doi: 10.1159/000169050.

20. Serena G., D’Avino P., Fasano A. Celiac Disease and Non-celiac Wheat Sensitivity: State of Art of Non-dietary Therapies. Front Nutr. 2020; 7:152. doi: 10.3389/fnut.2020.00152.

21. Slavin S.F. IgA Nephropathy as the Initial Presentation of Celiac Disease in an Adolescent. Pediatrics. 2021; 148(4):e2021051332. doi: 10.1542/peds.2021-051332.

22. Bobkova I.N., Vatazin A.V., Vetchinnikova O.N. Chronic kidney disease (CKD). Clinical guidelines. 2024. [Electronic resource]. URL: https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf. (date of the application: 29.01.2025) [In Russian].

23. Shilov E.M., Bobkova I.N., Kolina I.B. Clinical guidelines for the diagnosis and treatment of IgA nephropathy. Nephrology. 2015; 19(6): 83-92 [In Russian].

24. Wu J., Hu Z., Wang Y. et al. Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy. Histopathology. 2021; 78(6):882-895. doi: 10.1111/his.14318.

25. Khairwa A. Indian scenario of IgA nephropathy: a systematic review and meta-analysis. Afr. Health Sci. 2021; 21(1):159-165. doi: 10.4314/ahs.v21i1.21-54.

26. Gleeson P.J., O’Shaughnessy M.M., Barratt J. IgA nephropathy in adults—treatment standard, Nephrology Dialysis Transplantation. 2023; 38(11):2464-2473. doi: 10.1093/ndt/gfad146.

27. Trimarchi H., Barratt J., Cattran D.C. et al. IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003.

28. Gharavi A.G., Yan Y., Scolari F. et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat. Genet. 2000; 26(3):354-357. doi: 10.1038/81677.

29. Wakai K., Kawamura T., Endoh M. et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol. Dial. Transplant. 2006; 21:2800-2808. doi: 10.1093/ndt/gfl342.

30. International IgAN Prediction Tool at biopsy — Adults calculator. 2019. [Электронный ресурс]. URL: https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-adults. (дата обращения: 29.01.2025).

31. Bartosik L.P., Lajoie G., Sugar L. et al. Predicting progression in IgA nephropathy. Am. J. Kidney Dis. 2001; 38:728-735. doi: 10.1053/ajkd.2001.27689.

32. Moroni G., Longhi S., Quaglini S. et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol. Dial. Transplant. 2013; 28:1305-1314. doi: 10.1093/ndt/gfs472.

33. Rovin B.H., Adler S.G., Barratt J. et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases. Kidney Int. 2021; 100:753-779. doi: 10.1016/j.kint.2021.05.015.

34. Patrick J. Gleeson, Michelle M. O’Shaughnessy, Jonathan Barratt. IgA nephropathy in adults — treatment standard. Nephrol. Dial. Transplant. 2023; 38:2464-2473. doi: 10.1093/ndt/gfad146.

35. Praga M., Gutiérrez E., González E. et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 2003; 14(6):1578-1583. doi: 10.1097/01.asn.0000068460.37369.dc.

36. Zhao Y., Fan H., Bao B.Y. Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Iran J. Public Health. 2019; 48(9):1577-1588. doi: 10.18502/ijph.v48i9.3014.

37. Sigitova O.N. Treatment of arterial hypertension in patients with chronic kidney disease from the standpoint of the 2023 European guidelines. Kazan Medical Journal. 2024; 105(4):607-621. doi: 10.17816/KMJ626252 [In Russian].

38. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020; 383:1436-1446. doi: 10.1056/NEJMoa2024816.

39. Heather N. Reich and Jürgen Floege. Cl. J. Am. Soc. Nephrol. 2022; 17(8): 1243-1246. doi: 10.2215/CJN.02710322.

40. The E-KCG, Herrington W.G., Staplin N. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2023; 388:117-127. doi: 10.1056/NEJMoa2204233.

41. EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol. Dial. Transplant. 2022; 37:1317-1329. doi: 10.1093/ndt/gfac040.

42. Braunwald E. Gliflozins in the management of cardiovascular disease. N. Engl. J. Med. 2022; 386:2024-2034. doi: 10.1056/NEJMra2115011.

43. Donadio J.V., Grande J.P., Bergstralh E.J. et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J. Am. Soc. Nephrol. 1999; 10(8):1772-1777. doi: 10.1681/ASN.V1081772.

44. Hogg R.J., Lee J., Nardelli N. et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin. J. Am. Soc. Nephrol. 2006; 1(3):467-474. doi: 10.2215/CJN.01020905.

45. Strippoli G.F., Manno C., Schena F.P. An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism. Am. J. Kidney Dis. 2003;41(6):1129–39. doi: 10.1016/s0272-6386(03)00344-5.

46. Rehnberg J., Symreng A., Ludvigsson J.F. et al. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish PopulationBased Cohort Study. J. Am. Soc. Nephrol. 2021; 32(2):411-423. doi: 10.1681/ASN.2020060848.

47. Yang D., He L., Peng X. et al. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Ren. Fail. 2016; 38:242-248. doi: 10.3109/0886022X.2015.1128251.

48. Pozzi C., Bolasco P.G., Fogazzi G.B. et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353:883-887. doi: 10.1016/S0140-6736(98)03563-6.

49. Lv J., Zhang H., Wong M.G. et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017; 318:432-442. doi: 10.1001/jama.2017.9362.

50. Lv J., Wong M.G., Hladunewich M.A. et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022; 327:1888-1898. doi: 10.1001/jama.2022.5368.

51. Rauen T., Eitner F., Fitzner C. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 2015; 373:2225-2236. doi: 10.1056/NEJMoa1415463.

52. Rauen T., Wied S., Fitzner C. et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; 98:1044-1052. doi: 10.1016/j.kint.2020.04.046.

53. Lv J., Zhang H., Chen Y. et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am. J. Kidney Dis. 2009; 53:26-32. doi: 10.1053/j.ajkd.2008.07.029.

54. Han S., Yao T., Lu Y. et al. Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis. Front. Pharmacol. 2021; 11:539545. doi: 10.3389/fphar.2020.539545.

55. Mel`nichenko G.A., Belaya Zh.E., Rozhinskaya L.Ya. Federal clinical guidelines for the diagnosis, treatment and prevention of osteoporosis. Problems of endocrinology. 2017; 63(6):392-426. doi: 10.14341/probl2017636392-426

56. Barratt J., Lafayette R., Kristensen J. et al. NefIgArd Trial Investigators. Results from part A of the multi-center, doubleblind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023; 103(2):391-402. doi: 10.1016/j.kint.2022.09.017.

57. Ma F., Yang X., Zhou M. et al. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. J. Nephrol. 2020; 33(6):1241-1250. doi: 10.1007/s40620-020-00752-x.

58. Liu L.J., Yang Y.Z., Shi S.F. et al. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am. J. Kidney Dis. 2019; 74(1):15-22. doi: 10.1053/j.ajkd.2019.01.026.

59. Hou F.F., Xie D., Wang J. et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw. Open. 2023; 6(2):e2254054. doi: 10.1001/jamanetworkopen.2022.54054.

60. Ma F., Yang X., Zhou M. et al. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. J. Nephrol. 2020; 33(6):1241-1250. doi: 10.1007/s40620-020-00752-x.

61. Hernández-Rodríguez J., Carbonell C., Mirón-Canelo J.A. et al. Rituximab treatment for IgA vasculitis: A systematic review. Autoimmun. Rev. 2020; 19(4):102490. doi: 10.1016/j.autrev.2020.102490.

62. Gleeson P.J., O’Shaughnessy M.M. and Barratt J. IgA nephropathy in adults—treatment standard. Nephrol Dial Transplant, 2023, 38, 2464–2473 https://doi.org/10.1093/ndt/gfad146 Downloaded from https://academic.oup.com/ndt/article/38/11/2464/7221084 by guest on 25 December 2024